207 related articles for article (PubMed ID: 27793017)
1. Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients.
Huang L; Wei Y; Shen S; Shi Q; Bai J; Li J; Qin S; Yu H; Chen F
Oncotarget; 2017 Apr; 8(17):29346-29354. PubMed ID: 27793017
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chen H; Xue L; Liu L; Li P
J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study.
Guo Y; Tang J; Huang XE; Cao J
Medicine (Baltimore); 2019 Feb; 98(6):e13908. PubMed ID: 30732125
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
Wu Q; Fu Y; Wen W; Xi T; Zhao G
J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
[TBL] [Abstract][Full Text] [Related]
7. Apatinib combined with S-1 as second-line therapy in advanced gastric cancer.
Qiu ZY; Qin R; Tian GY; Zhang Z; Chen M; He H; Xi Y; Wang Y
Medicine (Baltimore); 2021 Apr; 100(17):e25630. PubMed ID: 33907117
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer.
Chen HD; Zhou J; Wen F; Zhang PF; Zhou KX; Zheng HR; Yang Y; Li Q
J Cancer Res Clin Oncol; 2017 Feb; 143(2):361-368. PubMed ID: 27798730
[TBL] [Abstract][Full Text] [Related]
9. Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease.
Wang Y; Bi M; Zhang H; Gao Z; Zhou H; Chang S
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e528-e530. PubMed ID: 28028915
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
[TBL] [Abstract][Full Text] [Related]
11. Treatment effect of apatinib combined chemotherapy as second-line or above therapy in patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.
Zhang F; Yin Y; Ni T; Zhang M; Zhou Z; Sun X; Kuang W; Li P
Pharmazie; 2020 Aug; 75(8):389-394. PubMed ID: 32758339
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study.
Du Y; Cao Q; Jiang C; Liang H; Ning Z; Ji C; Wang J; Zhou C; Jiang Z; Yu C; Li L; Zhao Y; Xu Y; Xu T; Hu W; Wang D; Cheng H; Wang G; Zhou J; Wang S; Zhang Y; Hu Z; Li X; Lu D; Zhang J; Xie H; Sun G
Cancer Med; 2020 Jul; 9(14):5008-5014. PubMed ID: 32441892
[TBL] [Abstract][Full Text] [Related]
13. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting.
Leng J; Li DR; Huang LM; Ji XH; Wang DL
Medicine (Baltimore); 2019 Sep; 98(36):e16967. PubMed ID: 31490378
[TBL] [Abstract][Full Text] [Related]
14. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
[TBL] [Abstract][Full Text] [Related]
15. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
Li J; Qin S; Xu J; Guo W; Xiong J; Bai Y; Sun G; Yang Y; Wang L; Xu N; Cheng Y; Wang Z; Zheng L; Tao M; Zhu X; Ji D; Liu X; Yu H
J Clin Oncol; 2013 Sep; 31(26):3219-25. PubMed ID: 23918952
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer.
Yang Y; Wu X; Li F; Wang N; Zhang M; Sun T; Chen Z
J Cancer Res Ther; 2019; 15(2):365-369. PubMed ID: 30964112
[TBL] [Abstract][Full Text] [Related]
18. [Summary of clinical research progression of apatinib combined with docetaxel in second-line treatment of advanced gastric cancer].
Yang MD; Gao J; Liu XL; Yang WH; Lu HX
Zhonghua Zhong Liu Za Zhi; 2020 Jul; 42(7):594-597. PubMed ID: 32842450
[No Abstract] [Full Text] [Related]
19. Efficacy of apatinib on multiple advanced-stage nongastric cancers.
Wu X; Wang H; Wu Y; Jin J; Zhan Y; Zhu G; Zhang F; Zhang C; Gan J; Li W
J Cancer Res Ther; 2019; 15(4):836-841. PubMed ID: 31436240
[TBL] [Abstract][Full Text] [Related]
20. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
[No Abstract] [Full Text] [Related]
[Next] [New Search]
